Skip to main content
SpringerLink
Log in

Risk of abnormal tissue growth with fingolimod: Canadian review

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Health Canada. Summary Safety Review - GILENYA (fingolimod) - Abnormal Tissue Growth (Neoplasms). Internet Document : 14 Sep 2015. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/gilenya-eng.php.

  2. Health Canada. Information Update - Multiple sclerosis drug Gilenya (fingolimod): Safety information on the risk of skin cancer and a rare brain infection. Internet Document : 30 Sep 2015. Available from: URL: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55160a-eng.php.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of abnormal tissue growth with fingolimod: Canadian review. Reactions Weekly 1626, 8 (2016). https://doi.org/10.1007/s40278-016-22589-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-22589-x

Search

Navigation